---
title: "NovoCure Limited (NVCR.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/NVCR.US.md"
symbol: "NVCR.US"
name: "NovoCure Limited"
industry: "Health Care Equipment"
---

# NovoCure Limited (NVCR.US)

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Location | US Market |
| Website | [www.novocure.com](https://www.novocure.com) |

## Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:14.000Z

**Overall: C (0.59)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 59 / 185 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.17% |  |
| Net Profit YoY | -18.60% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.73 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.27B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 642.27M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -50.60% | E |
| Profit Margin | -27.66% | E |
| Gross Margin | 73.25% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.17% | B |
| Net Profit YoY | -18.60% | D |
| Total Assets YoY | 11.39% | B |
| Net Assets YoY | -5.39% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -361.54% | D |
| OCF YoY | 11.17% | B |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.50 | C |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 74.92% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - NovoCure Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-50.60%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-27.66%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "73.25%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.17%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.60%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "11.39%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.39%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-361.54%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "11.17%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.50",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "74.92%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Inspire Medical (US.INSP) | A | B | A | A | B | A |
| 02 | Delcath (US.DCTH) | C | A | A | A | A | A |
| 03 | Intuitive Surgical (US.ISRG) | A | B | C | A | B | B |
| 04 | Stryker (US.SYK) | A | B | C | C | B | B |
| 05 | Boston Scientific (US.BSX) | B | B | C | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.16 | 132/181 | - | - | - |
| PB | 3.73 | 82/181 | 5.51 | 4.47 | 3.87 |
| PS (TTM) | 1.98 | 55/181 | 3.21 | 2.41 | 2.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 4 | 57% |
| Overweight | 1 | 14% |
| Hold | 2 | 29% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 11.36 |
| Highest Target | 39.00 |
| Lowest Target | 13.50 |

## References

- [Company Overview](https://longbridge.com/en/quote/NVCR.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/NVCR.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/NVCR.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.